Related by context. All words. (Click for frequent words.) 61 fosbretabulin 59 RhuDex R 58 CALGB 58 BR.# 58 multicentric 57 nonmetastatic 57 refractory colorectal cancer 57 huN# DM1 57 metastatic pancreatic 57 Gynecologic Oncology Group 57 Phase 1b clinical trials 56 histologically confirmed 56 Multiple Myeloma MM 56 ASCO GU 56 underwent resection 56 demonstrated antitumor activity 56 pT2 55 papillary renal cell carcinoma 55 essential thrombocythemia ET 55 gefitinib Iressa 55 beta 1a 55 Systemic Sclerosis 55 EORTC 55 ZACTIMA 55 Phase Ib II 55 CHAMPION PCI 55 Phase #b/#a clinical 55 prospective nonrandomized 54 patientswith 54 ErbB2 positive 54 metastatic gastric 54 RhuDex ™ 54 colorectal carcinoma 54 observational cohort study 54 lymphoid malignancies 54 CALGB # [002] 54 prostate carcinoma 54 BioNumerik 54 NCCTG 54 pediatric acute lymphoblastic 54 Randomized Evaluation 54 prospective observational 54 recurrent glioblastoma multiforme 54 prostate cancer CaP 54 sunitinib Sutent 54 Tesmilifene 54 histone deacetylase inhibitor 54 relapsed MM 54 stage IIIB 53 Daclizumab 53 DF HCC 53 polycythemia vera essential thrombocythemia 53 Phase Ib Clinical Trial 53 Edge STudy 53 CC genotype 53 somatostatin analog 53 neoadjuvant 53 KRAS mutations occur 53 clinically localized prostate 53 paclitaxel poliglumex 53 Prostate Lung Colorectal 53 retrospectively analyzed 53 REVIVE Diabetes 53 undergone radical prostatectomy 53 Cardiotoxicity 53 pharmacokinetic PK study 53 GW# [003] 53 ASSERT 53 Gastrointestinal Oncology 53 NSABP B 53 Preclinical Study 53 thalidomide Thalomid 53 NABTT 53 completely resected 53 syngeneic 53 Pediatric Oncology Branch 53 Delcath Phase III 53 dose escalation clinical 53 HORIZONS AMI trial 53 Unstable Angina 53 HepaSphere 53 allogeneic hematopoietic stem cell 53 multicenter phase 53 ICON7 53 Teriflunomide 53 Novel Therapeutic 53 vinca alkaloid 53 AIR2 Trial 53 Prospective Randomized 52 Renal Cell Carcinoma RCC 52 Phase 2b Clinical Trial 52 Non Alcoholic Steatohepatitis 52 receptor tyrosine kinase inhibitor 52 ARRY # 52 neoadjuvant chemotherapy 52 clinicopathological 52 preclinical efficacy 52 lymphoproliferative disorders 52 HDAC Inhibitor 52 efficacy evaluable 52 evaluating tivozanib 52 NSABP 52 PRESEPT 52 Myeloid 52 p# biomarker 52 randomized Phase III 52 Phase III Psoriasis 52 mCRPC 52 Group RTOG 52 prospective randomized multicenter 52 ILLUSTRATE 52 Triapine R 52 multicenter clinical trials 52 Prolongs Survival 52 Phase Ib clinical 52 immunomodulatory therapy 52 antiretroviral naïve 52 Blinatumomab 52 Kahalalide F 52 gene polymorphism 52 phase IIb study 52 REALITY Trial 52 multicenter prospective 52 Onrigin 52 RE LY trial 51 Hsp# Inhibitor 51 Proc Am Soc 51 MIVI TRUST 51 HNSCC 51 histone deacetylase HDAC inhibitor 51 thetreatment 51 pancreatic islet cell 51 metastatic neuroendocrine tumors 51 EURIDIS 51 chromosome #p# [002] 51 Late Breaker 51 BCIRG 51 PTI CORR 51 Anticancer Drug 51 TAXUS V 51 GG genotype 51 COPERNICUS 51 MEND CABG 51 evaluating mipomersen 51 number NCT# ClinicalTrials.gov 51 Trial PCPT 51 Intervention Trial 51 laparoscopic radical nephrectomy 51 Epirubicin 51 evaluating REVLIMID 51 Phase Ib IIa clinical 51 XIENCE V Stent System 51 multicentre prospective 51 underwent radical prostatectomy 51 Tyrosine Kinase Inhibitors 51 metastatic renal cell carcinoma 51 Group NCIC CTG 51 YONDELIS R 51 Myelodysplastic Syndrome MDS 51 Multiple Ascending Dose 51 Radiation Therapy Oncology 51 hematological malignancy 51 Severe Sepsis 51 Observational Study 51 Ovarian PLCO Cancer 51 JAK2 Inhibitor 51 Antitumor 51 pancreatic adenocarcinoma 51 Acute Decompensated Heart Failure 51 advanced hepatocellular carcinoma 51 NOD mouse 51 childhood acute lymphoblastic 51 phase IIIb 51 Hepatocellular Carcinoma HCC 51 Acute Stroke 51 Amrubicin 51 EchoCRT 51 IFOS 51 satraplatin Phase 51 sunitinib malate 51 Group B CALGB 51 ENGAGE AF TIMI 51 sorafenib Nexavar 51 Panzem ® 51 lorcaserin Phase 51 metastatic malignant 51 Phase 2b Trial 50 CRLX# 50 neratinib 50 SWOG 50 familial amyloidotic polyneuropathy FAP 50 DEB# 50 liposomal formulation 50 Platinol ® cisplatin 50 Soft Tissue Sarcoma 50 PARTNER Trial 50 PEGylated interferon beta 1a 50 kidney urologic 50 randomized Phase 2b 50 placebo controlled clinical 50 Antiviral Therapy 50 ECTRIMS 50 Carotid Revascularization Endarterectomy vs. 50 Estrogen Receptor 50 substudy 50 Bosutinib 50 CDKN2A 50 ANTEGREN 50 OvaRex MAb 50 thymoma 50 Quinamed 50 Val HeFT 50 multicenter randomized controlled 50 relapsing multiple sclerosis 50 cisplatin gemcitabine 50 Randomized trials 50 Hypertriglyceridemia 50 haematologic malignancies 50 prospectively evaluated 50 Granted Orphan Drug 50 Zybrestat 50 multicenter randomized clinical 50 ALN TTR 50 neoadjuvant treatment 50 CaPSURE 50 Patient Registry 50 rs# [004] 50 CARE HF 50 Novel Inhibitor 50 longitudinal observational study 50 clevidipine 50 Multicenter AIDS 50 BCR ABL inhibitor 50 Cimzia TM 50 ZYBRESTAT fosbretabulin 50 Newly Diagnosed Multiple Myeloma 50 TG MV 50 prospective observational cohort 50 cytoreductive nephrectomy 50 Phase Ib study 50 multicentre study 50 retrospective cohort 50 ASCT 50 HCV Protease Inhibitor 50 Developmental Therapeutics 50 prospective multicenter 50 retrospective cohort study 50 Decompensated Heart Failure 50 COU AA 50 vivo validation 50 Cloretazine 50 androgen suppression 50 EORTC NCI 50 LUMINATE 50 pharmacokinetic PK 50 Etiology 50 vismodegib 50 Initiates Phase 2b 50 chronic myocardial ischemia 50 acadesine 50 Polymorphisms 50 Superficial Femoral Artery 49 Microalbuminuria 49 IL#B 49 Phase 1b trial 49 Omacetaxine 49 IPAH 49 Mantle Cell Lymphoma 49 IMiDs ® compound 49 Trandolapril 49 Velcade bortezomib 49 HIV seronegative 49 multivariate Cox 49 pharmacodynamic PD 49 basal cell carcinoma BCC 49 TRA 2P 49 Centro Monzino 49 Hemodialysis Patients 49 Acute Coronary Syndromes ACS 49 abacavir Ziagen 49 HDL Selective Delipidation 49 ALN HTT 49 TNM staging 49 PANVAC VF 49 NOD SCID mice 49 Hematologic Malignancies 49 PEG IFN 49 AACR #st Annual Meeting 49 Fibromyalgia syndrome 49 Allogeneic 49 Doxil ® 49 SYN# 49 randomized blinded 49 histologically proven 49 Myelodysplastic Syndrome 49 Tumor Registry 49 CAPRIE 49 prospectively defined 49 CSPG 49 Febuxostat 49 Hematologic 49 MGUS 49 recurrent glioma 49 Arranon 49 Endovascular Valve Edge 49 cutaneous melanoma 49 Advanced Renal Cell 49 Cutaneous T 49 mITT population 49 Tumor Microenvironment 49 microbiologically evaluable 49 Relapsing remitting 49 RE LY ® 49 Phase III Clinical Trial 49 PROLARIS 49 Complications Trial 49 HIV seropositive 49 Myocardial Infarction TIMI Study 49 GELA 49 Vascular Disease Foundation 49 Arteriosclerosis 49 Movement Disorder 49 multiple myeloma MM 49 Ischemic 49 Acute Ischemic Stroke 49 caspase inhibitor 49 PCWP 49 Gastric Cancer 49 HGPIN 49 Phase 1a clinical 49 alpha1 antitrypsin deficiency 49 SIMPADICO 49 dasatinib Sprycel 49 Chronic lymphocytic leukemia 49 Oncologic 49 Introgen ADVEXIN 49 Acute myeloid leukemia 49 Exelixis XL# 49 Risk Stratification 49 Polymorphism 49 teriflunomide 49 Phase IIIb study 49 ACOMPLIA R 49 variant rs# 49 RE LY 49 SORT OUT III 49 ADVEXIN therapy 49 Stage IIIA 49 smoldering myeloma 49 radical retropubic prostatectomy 49 Triapine 49 Biological Therapy 49 Pancreas Cancer 48 CTEPH 48 TEMSO 48 Acute Myeloid Leukemia AML 48 Thrombophilia 48 Hepatocellular Carcinoma 48 Asthma Intervention 48 Temodar ® 48 genitourinary cancers 48 Intervention Trial GAIT 48 phase IIa clinical 48 #p# [003] 48 HMG CoA reductase inhibitors 48 IL# PE#QQR 48 neurological manifestations 48 Molecular Carcinogenesis 48 RECIST Response Evaluation Criteria 48 multivariate analyzes 48 alpha antagonist 48 genomewide association study 48 Pharmacodynamic 48 Demonstrates Sustained 48 Phase 2a Clinical Trial 48 Cellular Immunotherapy 48 investigational therapies 48 prognostic biomarker 48 null responder 48 SUTENT ® 48 Evoltra ® 48 SSc 48 MEND CABG II 48 REGARDS 48 Iron Overload 48 pharmacokinetics PK 48 SABCS 48 #st Annual Meeting 48 Hematological 48 gemcitabine Gemzar ® 48 ABCB1 48 Cloretazine ® 48 Systemic Lupus Erythematosus SLE 48 lorvotuzumab mertansine 48 ICAAC IDSA 48 ECASS 48 Angiolix 48 normotensive 48 renal cell carcinomas 48 alemtuzumab Campath 48 aMCI precursor 48 Cardiovascular Magnetic Resonance 48 germline mutations 48 Hospital Clínic 48 intra abdominal abscess 48 Kaplan Meier analysis 48 Trial NLST 48 uremic pruritus 48 eribulin mesylate 48 Heart Transplant Recipients 48 Ocrelizumab 48 renal tumors 48 pharmacodynamic profiles 48 advanced adenoma 48 allogeneic bone marrow 48 clinicopathologic 48 HIV HCV coinfected 48 ISTH 48 Oral Compound 48 Digital Mammographic Imaging 48 MYTHOS trial 48 AML MDS 48 histone acetyltransferase 48 decitabine 48 unstable angina pectoris 48 NCIC Clinical Trials 48 Antisoma AS# 48 STRIDE PD 48 docetaxel pretreated 48 ug dose 48 squamous cell carcinoma SCC 48 ExTRACT TIMI 48 TRO# 48 colorectal adenoma 48 Neuroendocrine Tumor 48 de novo AML 48 Cohort Consortium 48 multivariable adjusted 48 Simulect 48 Renal Artery 48 Phase III HEAT 48 fludarabine cyclophosphamide 48 AA Amyloidosis 48 Acute Coronary Syndromes 48 ENDEAVOR IV 48 beta1 48 Subtype 48 psoriatic arthritis PsA 48 PDE# inhibitors 48 CLARITY TIMI 48 Liraglutide Effect 48 retrospective observational study 48 cardio renal 47 experimental autoimmune encephalomyelitis 47 Phase III psoriasis 47 placebo controlled Phase III 47 catechol O methyltransferase COMT 47 Asthma COPD 47 Telatinib 47 pegylated interferon alfa 2b 47 HLA DR4 47 Chronic Heart Failure 47 APEX AMI trial 47 Hedgehog antagonist 47 MTHFR 47 Stenting Trial CREST 47 seropositivity 47 Adrenergic 47 Neuroprotection 47 Glioma 47 ATTR CM 47 Multicenter 47 Cell Transplant 47 HIV Cohort Study 47 pharmacokinetic pharmacodynamic 47 #nd EORTC NCI 47 MabCampath 47 ASGCT 47 vitro cytotoxicity 47 Yondelis ® 47 Acute MI 47 clinical pharmacology studies 47 SNCA 47 PEG SN# 47 lumiliximab 47 Multi Ethnic Study 47 prospective multicenter study 47 CLARITY study 47 Onconase 47 PCa 47 Clinical Antipsychotic Trials 47 conducted retrospective cohort 47 ACRIN 47 blinded randomized placebo controlled 47 Neuro Oncology SNO 47 rs# rs# 47 novel histone deacetylase 47 glatiramer acetate GA 47 Angiox R 47 Adrenomyeloneuropathy AMN 47 Squalamine 47 hypereosinophilic syndrome 47 Bucindolol 47 PFO migraine 47 J Foot Ankle 47 pomalidomide 47 Aneurysm Repair 47 Lymphoma Leukemia 47 clinically evaluable 47 depsipeptide 47 Resuscitation Outcomes Consortium 47 epithelial tumors 47 Trofex 47 soluble receptor 47 randomizing patients 47 Stereotactic Body Radiation Therapy 47 Hervé Hoppenot President 47 Acute Myocardial Infarction 47 darunavir r 47 IIa clinical 47 Fingolimod 47 ABCSG 47 Cimzia certolizumab pegol 47 Eluting Stent 47 CIMZIA ™ 47 Interferon beta 47 commercialize deforolimus 47 chemoradiotherapy 47 Podium Presentation 47 SNP rs# [002] 47 Screening Trial DMIST 47 undergoing coronary angiography 47 Bendamustine 47 NICE SUGAR 47 susceptibility loci 47 BENICAR 47 NIDDM 47 controlled multicenter 47 Multicenter Study 47 pCR 47 AVONEX ® 47 adjuvant endocrine therapy 47 Pamidronate 47 Hyperlipidemia 47 TAXUS IV 47 Pancreatic 47 Treatment Outcome 47 epoetin alpha 47 Zenvia Phase III 47 PhG alpha 1 47 carotid artery stenting CAS 47 ONTARGET 47 mg p = 47 Pharmacokinetic parameters 47 Clinical Trials Consortium 47 CEQ# 47 SinuNase ™ 47 NSTE ACS 47 tolerability pharmacokinetics 47 Solid Tumors 47 BCG refractory 47 Dr. McHutchison 46 HLA DR2 46 phase IIa 46 Triolex 46 lymphoblastoid cell lines 46 ENMD # 46 cortical stimulation 46 lipid lowering agents 46 prospective multicentre 46 Valproic acid 46 cytogenetic abnormalities 46 prospective observational studies 46 locoregional 46 HBeAg negative patients 46 rALLy clinical trial 46 metastatic malignant melanoma 46 Hepatotoxicity 46 PROPEL 46 XIENCE V Everolimus Eluting 46 Islet Cell 46 Echocardiographic 46 antiangiogenic agent 46 Glioblastoma Multiforme 46 abnormal cytology 46 EBMT 46 polyarticular 46 CanAg 46 Hypogonadism 46 serine protease inhibitor 46 Severe Asthma 46 Septic Shock 46 NOD mice 46 NATRECOR R 46 Apoptone 46 TAXUS TM 46 Carcinoid 46 longitudinal cohort study 46 Resource Exchange AGRE 46 Liprostin 46 Swedish Mammography Cohort 46 Intervention Effectiveness CATIE 46 IASLC 46 malignant neoplasm 46 By JENNIFER LEARN 46 plus COPEGUS 46 TQT 46 postmenopausal osteoporotic women 46 Temodar temozolomide 46 Arimidex Tamoxifen Alone 46 Stent Thrombosis 46 PICSO ® 46 ACCLAIM II 46 miRagen 46 rALLy trial 46 MADIT CRT 46 GRNCM1 46 Acute Liver Failure 46 Biotherapy 46 histopathological 46 myeloproliferative disorder 46 FDG PET imaging 46 % CI #.#-#.# [003] 46 monoclonal anti 46 lymphadenectomy 46 haematologic 46 ER CHOP 46 cardiovascular calcification 46 Alzhemed TM 46 #:# -# [003] 46 observational cohort 46 Rheumatoid 46 Virium 46 Plenaxis TM 46 PLX MS 46 EACTS 46 ORAL HYCAMTIN 46 T1DM 46 Pharmacologic 46 Acute lymphoblastic leukemia 46 NCCTG N# 46 logistic regression analysis 46 Insulin Resistance 46 ADHERE 46 Vascugel 46 Malignant Lymphoma 46 Oncogenic 46 Urocortin 2 46 ImmuKnow R 46 BrachySil ™ 46 thorough QTc 46 Investigator Initiated 46 HoFH 46 hepatocellular carcinoma HCC 46 OHR/AVR# 46 gene polymorphisms 46 novel vascular disrupting 46 Group ECOG 46 Histopathological 46 Ovarian Cancer Screening 46 TT genotype 46 evaluating Prochymal 46 Cystic 46 LibiGel Phase III 46 Gorlin syndrome 46 HeFT 46 SEER database 46 Phase 2b kidney transplant 46 Alpha Tocopherol Beta Carotene 46 multiple sclerosis Crohn disease 46 ELCAP 46 FDG PET CT 46 GH deficiency 46 INTERCEPT platelets 46 HYVET 46 pemphigus vulgaris 46 atypical Hemolytic Uremic Syndrome 46 PROactive study 46 HHV 6 46 Certican 46 ESHO 46 locoregional disease 46 Score TOS 46 PERSEUS 46 AVOREN 46 VKORC1 46 Avonex interferon beta 1a 46 epoetin beta 46 OZURDEX 46 preclinically 46 micrometastases 46 hematopoietic cell 46 Glatiramer acetate 46 StemEx R 46 pain palliation 46 Non inferiority 46 subanalysis 46 genomic biomarker 46 AtherOx 46 LDH lactate dehydrogenase 45 Advanced Heart Failure 45 antiphospholipid syndrome APS 45 multivariable analysis 45 null responder HCV 45 ISTODAX ® 45 Stenting Trial 45 cyclophilin inhibitors 45 Telintra 45 Cachexia 45 CATIE AD 45 Thrombolysis 45 International OARSI 45 genetic polymorphisms 45 Hp2 2 45 PsA 45 Anceta 45 Primary endpoints 45 Laryngeal Cancer 45 clinico pathological 45 Waldenstrom Macroglobulinemia 45 Campath alemtuzumab 45 Postmenopausal hormone therapy 45 International Myeloma Workshop 45 recurrent glioblastoma 45 Functional Neurosurgery 45 progressive demyelinating disease 45 Biomerk Tumorgrafts 45 dyslipidaemia 45 SCCHN 45 univariate 45 Rakai Uganda 45 psoriasis rheumatoid arthritis 45 Oxidized LDL 45 EMPHASIS HF 45 varespladib 45 Systemic lupus erythematosus SLE 45 ADONIS 45 Multicenter Phase 45 Zenvia ™ 45 anti fibrotic 45 Other OTC BVTI 45 desvenlafaxine succinate 45 NCT# ClinicalTrials.gov 45 cholangiocarcinoma 45 Musculoskeletal Diseases 45 Solid Tumors criteria 45 Phase IIA 45 stem cell transplantations 45 Heart Failure Trial 45 advanced neuroendocrine tumors 45 C#Y 45 BCR ABL1 45 Myocardial Infarction 45 BRCA2 mutation carriers 45 KRAS mutation 45 alefacept 45 PSN# [002] 45 Neurogenic 45 LV dysfunction 45 demyelinating 45 mixed hyperlipidemia 45 Adult Stem Cell Therapy 45 Afib 45 univariate analyzes 45 achieved sustained virological 45 curative resection 45 Translational Oncology 45 RAPAFLO R 45 Prof. Gozes 45 CAMPATH 45 prognostic significance 45 Amplimexon 45 Thrombotic 45 Clavis Pharma ASA 45 unstable angina UA 45 serum lipid levels 45 Rheumatoid Arthritis RA 45 Cintredekin besudotox 45 autologous hematopoietic stem cell 45 Acute Promyelocytic Leukemia 45 ASNR 45 del 5q 45 Pediatric Endocrinology 45 Autoimmune Diseases 45 Microwave Ablation System 45 thoracoscopic lobectomy 45 Cerepro ® 45 sustained virological response 45 serum leptin 45 florbetaben 45 Immunodeficiency 45 PLCO 45 APTIVUS R 45 COPAXONE 45 GAMMAGARD 45 Fibromyalgia Syndrome 45 MELAS 45 Cytopathology 45 ASCEND HF 45 Endocrine Society #st 45 Statin therapy 45 Coronary Artery Calcium 45 Endeavor DES 45 Onrigin TM 45 ADVEXIN clinical 45 FRDA 45 Radiation Oncologists 45 T1D 45 Hematopoietic 45 Gynecological Cancer 45 Cervical Cytology 45 Clinicaltrials.gov 45 tumor subtypes 45 trodusquemine 45 BARI 2D 45 Survivor Study CCSS 45 invasive bladder 45 Connective Tissue Oncology 45 OLYMPIA registry 45 Intervention Effectiveness 45 Prostate Cancer Prevention 45 Rebif interferon beta 1a 45 HPTN 45 Female Urology 45 allogeneic hematopoietic cell 45 T2DM 45 UEGW 45 Lp PLA 2 45 sCD# 45 mTOR inhibitor 45 Gynecologic Cancer Society 45 autoimmune encephalitis 45 USpella 45 VADT 45 histological subtype 45 Mol Med 45 Glioblastoma Multiforme GBM 45 Neuroendocrine tumors 45 Clusterin 45 Bronchiectasis 45 amnestic MCI 45 malignant phenotype 45 Montalescot 45 Alemtuzumab 44 CPDR 44 Cancer Genetic Markers 44 Hematology Meeting 44 GPNMB expression 44 Relapsing Remitting Multiple Sclerosis 44 Neovascular Age Related Macular 44 mass spectrometry GC 44 MBP# dirucotide 44 ischemic cardiomyopathy 44 glucocorticoid induced osteoporosis 44 lymph node dissection 44 National Oncologic PET 44 briakinumab 44 SF #v# 44 busulfan 44 Prospective Multicenter 44 MERLIN TIMI 44 HLA DRB1 * 44 neuropathologic 44 prognostic variables 44 ISPOR 44 MAPT 44 Myelodysplastic Syndromes MDS 44 acute humoral rejection 44 PsA ulcerative colitis 44 Keystone Symposia 44 ST Segment Elevation 44 etiologic 44 CAMMS# 44 multicenter trials 44 Phenotype 44 Women Ischemia Syndrome 44 SJIA 44 Chemophase 44 FDG PET 44 Congenital Emphysema 44 antithrombotic therapy 44 Leukemia lymphoma 44 atherothrombotic 44 treat relapsing forms 44 BCNS 44 MADIT II 44 PCI ExTRACT TIMI 44 Chronic HCV 44 Pivotal Trial 44 SSc patients 44 Zevalin consolidation 44 solid organ transplantation 44 myogenic cell 44 Evaluation WISE 44 Cloretazine R 44 preserved LVEF 44 natriuretic peptide 44 diabetes mellitus DM 44 mycophenolate mofetil MMF 44 NSTEMI 44 pharmacokinetic characteristics 44 serum GGT 44 metastatic RCC 44 EOX 44 Ocular Pharmacology 44 Dialysis Outcomes 44 Netherlands Cohort Study 44 Hematopathology 44 ACEI 44 Acute Lymphoblastic Leukaemia 44 Colorectal Cancer Study 44 associated vasculitis 44 samalizumab 44 Limb Salvage 44 Autoimmunity 44 Sunitinib malate 44 Diabetes Complications 44 Baseline characteristics 44 Pituitary 44 Idiopathic Pulmonary Fibrosis IPF 44 AFFiRiS 44 2 microglobulin 44 Eculizumab 44 ADPKD 44 extracranial 44 Intravenous immunoglobulin 44 Noscira 44 FDG PET scans 44 Plaque Psoriasis 44 Adverse Event 44 Clinical Pharmacy 44 Bipolar Disorders 44 iSBTc 44 Digestive Diseases Week 44 multivariate logistic regression 44 Carfilzomib 44 Agendia BV 44 Aryplase 44 Neurobiological 44 susceptibility locus 44 Antihypertensive 44 Research Diagnostic Criteria 44 Immunohistochemistry 44 chromosome #q# [002] 44 HLA DR4 immune 44 Erythropoiesis Stimulating Agents 44 Arterial Disease 44 ORACLE MS 44 J. Clin 44 morphometric vertebral fractures 44 Biodesix 44 Talabostat 44 multiple logistic regression 44 MADIT CRT trial 44 Clinical Oncology Annual Meeting 44 1 diabetes T1D 44 Francophone du 44 metaanalysis 44 APRN BC 44 amnestic mild cognitive impairment 44 GRAVITAS trial 44 NNT = 44 International Verapamil SR 44 WHIMS 44 Baltimore Longitudinal Study 44 Pancreas Transplant 44 Thyroid Cancer 44 FRDA patients 44 Elisabeth Lindner CEO 44 ACR# ACR# 44 Paediatric Endocrinology 44 Acetonide 44 KIF6 gene variant 44 univariate analysis 44 MEMS ICs 44 FAMPYRA 44 ATACAND 44 J Consult Clin 44 EUS FNA 44 anthropometric measurements 44 underwent CABG 44 Neuroepidemiology 44 Investigational Drug 44 postintervention 44 glatiramer acetate 44 ABRF 44 neovascular age 44 Pediatr 44 S#.# [006] 44 localized prostate 44 Idiopathic Pulmonary Fibrosis 44 MADIT 44 Myelodysplastic syndrome 44 Communities ARIC study 44 periprocedural MI 44 Progressive Multifocal Leukoencephalopathy 44 schizophrenia CIAS 44 biostatisticians 44 familial aggregation